...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: USA ZHCLF investors

Tensamany,

After listening to the AGM presentation i to concluded that DM sound quite sincere about  future  BP deals, whatever that means.  He kept alluding to the benefits of a royalty structure that they have for both Rseverlogix and  Zenoth that 1 or both would have a deal soon.  Does that mean either company will get licensing deals on each and every indication  for either Zen3694  or Apabetalone.  To me it seems that right now BP are in the drivers seat and that BP's are extremely risk adverse in buyouts deals and IMO if we see something soon the deal structure will 100% benefit the BP that will be milestone based or staged on payouts for any deal and money will depend on an FDA drug registration.no risk to the BP if if Zen3694 or Apabetalone does get registered. My question to the board is that if we get a license deal how does help the shareholders for ZHCLF unless the BOD decides to do an IPO. It this market emvironment i don't see that happening. I would love to see 1  bBP do a complete staged buyout deal for both co's . rather than partnership deals or license deals but at this point i will take anything

 

Share
New Message
Please login to post a reply